API-1 (Synonyms: NSC 177223) |
Catalog No.GC18374 |
강력한 Akt/PKB 억제제인 API-1은 PH 도메인에 결합하여 Akt 막 전위를 억제합니다. API-1은 ~0.8μM의 IC50으로 Akt의 인산화 수준을 효율적으로 감소시킵니다. API-1은 PKB에 대해 선택적이며 PKC 및 PKA의 활성화를 억제하지 않습니다. API-1은 또한 TRAIL(TNF-related apoptosis-inducing ligand)과 상승 작용하여 apoptosis를 유도합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 36707-00-3
Sample solution is provided at 25 µL, 10mM.
API-1 is an inhibitor of Akt that reduces the level of phosphorylated Akt (IC50 = ~0.8 uM in OVCAR3 cells) by binding to Akt and blocking its translocation to the cell membrane. It reduces cell proliferation in various cancer cell lines, induces apoptosis, and, at a dose of 10 mg/kg per day, decreases tumor growth in a mouse xenograft model. API-1 inhibition of Akt leads to proteasomal degradation of the downstream mediator Mcl-1. Likely independent of Akt binding, API-1 inhibits cell growth (IC50s = 2-5 uM) and induces apoptosis in non-small cell lung and head and neck squamous cancer (NSCLC and HNSCC) cell lines with concomitant increases in caspase-3, -8, and -9 cleavage. It reduces the levels of cellular FLICE-inhibitory protein (c-FLIP), an important regulator of apoptosis, through ubiquitin- and proteasome-mediated degradation. It also has a synergistic effect on apoptosis in combination with TRAIL/APO-2L.The information regarding the reduction in phosphorylated Akt levels, IC50 value, translocation, cell proliferation, and xenograft tumor growth was drawn from a paper that has been retracted; however, the information specified in the retraction statement has not been included.
Review for API-1
Average Rating: 5
(Based on Reviews and 6 reference(s) in Google Scholar.)Review for API-1
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *